71 – 80 of 1938
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk
(
- Contribution to journal › Article
-
Mark
Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition
(
- Contribution to journal › Article
-
Mark
The pleiotropic role of proteoglycans in extracellular vesicle mediated communication in the tumor microenvironment
(
- Contribution to journal › Scientific review
-
Mark
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer : Results from the phase 3 PANTHER trial
(
- Contribution to journal › Article
-
Mark
Identification and validation of VEGFR2 kinase as a target of voacangine by a systematic combination of DARTS and MSI
(
- Contribution to journal › Article
-
Mark
Barriers and facilitators for individualized rehabilitation during breast cancer treatment- A focus group study exploring health care professionals' experiences
(
- Contribution to journal › Article
-
Mark
Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes
(
- Contribution to journal › Scientific review
-
Mark
Abstract P5-02-01: Analytical validation and prognostic potential of an automated digital scoring protocol for Ki67: An International Ki67 Working Group study
(
- Contribution to journal › Published meeting abstract
-
Mark
Abstract P1-18-10: Preoperative treatment of HER2-positive breast cancer in South Sweden. A retrospective, comprehensive survey of neo-adjuvant treated HER2-positve breast cancer in the SCAN-B project 2010-2017
2020) San Antonio Breast Cancer Symposium, 2019 In Cancer research. Supplement 80(Issue 4 Supplement). p.1-18(
- Contribution to journal › Published meeting abstract
-
Mark
Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer
(
- Contribution to journal › Article